ArticleDiscover nano2026
Green synthesis of Simarouba glauca seed-mediated silver nanoparticles: physicochemical characterization and cytotoxic mechanisms in HepG2 hepatocellular carcinoma cells.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to synthesize Simarouba glauca seed-mediated silver nanoparticles (Sg-AgNPs) through an eco-friendly approach and to evaluate their antioxidant, anti-inflammatory, and anticancer efficacy against HepG2 hepatocellular carcinoma cells. To characterize biosynthesized Sg-AgNPs' optical properties, functional groups, crystallinity, morphology, particle size, and elemental composition, UV-Visible spectroscopy, FT-IR, XRD, SEM, TEM, and EDX were used. Nanoparticles exhibiting a surface plasmon resonance peak at 430 nm and TEM showing 15-60 nm spherical particles. Studies showed considerable antioxidant, anti-inflammatory, and cytotoxic actions against HepG2 cells, with an IC₅₀ value of 42.7 µg/mL. Sg-AgNPs limit cancer cell growth via oxidative stress and apoptosis. These results demonstrate Simarouba glauca-mediated AgNPs as a durable and physiologically beneficial nanoplatform for hepatocellular carcinoma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.